K & S W Consult

K & S W Consult

Founded by Klaus Würtenberger, K & S W Consult operates as the investment and advisory vehicle for a private family's capital, anchored in the Lake Constance region of southern Germany. The firm's architecture reflects Würtenberger's executive career rather than a traditional wealth-management pedigree: his role as CFO and COO of Berlin Heart GmbH—a developer of ventricular assist devices—shaped an investment posture oriented toward medical technology companies where operational complexity is a barrier to entry. The firm concentrates on early-stage and seed investments in European life sciences, particularly biotech and medtech. Its approach relies on direct co-investments and special-purpose vehicles alongside a tight circle of repeat co-investors. Confirmed relationships include Santo Venture Capital, the Strüngmann family office known for backing BioNTech, and LBBW Venture Capital, the venture arm of Landesbank Baden-Württemberg, as well as Mangold Invest, a German industrial and medical-technology investor. This network targets clinical-stage and pre-commercial companies where regulatory expertise and manufacturing know-how are as critical as capital. K & S W Consult operates through at least two linked entities: the advisory firm itself and K & S W Invest GmbH, a dedicated investment vehicle. The office maintains a physical presence at Im Oberdorf 23 in Öhningen, a mixed-use property that serves as the firm's headquarters. The deliberate absence of a broader institutional team suggests a lean structure that relies on Würtenberger's direct involvement in deal selection and portfolio oversight, a model common among European single-family offices focused on a single vertical. What distinguishes K & S W Consult structurally is its operator-to-investor lineage. Instead of functioning as a diversified allocator, the firm concentrates on a sector—cardiovascular and broader medtech—where its principal has hands-on experience managing a regulated medical-device company through clinical trials, manufacturing scale-up, and eventual acquisition. This depth-of-domain model creates a sourcing advantage in a region dense with university-spun life sciences startups and a handful of family-backed co-investors who write checks only alongside proven operators.